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ABSTRACT 
Objective: To formulate and characterize. Phenobarbital sodium loaded sublingual patch using biodegradable, mucoadhesive, fast-dissolving 
natural polymer pullulan for immediate management of epileptic seizures. 
Methods: Phenobarbital sodium loaded sublingual patches were prepared by the solvent casting method and were subjected to various 
physicochemical evaluation parameters to find the optimized sublingual patch. The in vitro drug release study and kinetic model of the optimized 
formulation was also carried out. The stability study of the optimized Phenobarbital sodium loaded sublingual patch was also done. 
Results: From in vitro drug release study, it was found that Phenobarbital sodium loaded sublingual patch (S4) exhibited a maximum drug release 
of 96.24±1.27% at the end of 60 min compared to other formulations indicating a faster drug release from the formulation with release kinetics as 
Higuchi diffusion model. In fact, a notable release data was obtained between 0.5 to 8 min by all formulations, specifically S4 formulation 
(20.84±1.97% and 77.22±2.41% drug release at the end of 0.5 min and 8 min respectively) showed a better percentage release profile in 
comparison with other formulations. Such a trend is vital to deliver the drug at a faster rate to promote immediate effect for managing the fatal and 
complicated seizure. Considering the physicochemical property and in vitro drug release data, S4 formulation was regarded as an optimized one. 
The stability study also confirmed that S4 formulation is stable at refrigeration conditions. 
Conclusion: The formulated Phenobarbital sodium loaded sublingual patch is an effective drug delivery carrier which enables faster drug release to 
manage epileptic seizure. 
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INTRODUCTION 
Epilepsy is the third most common neurological disorder affecting 
almost 1% worldwide population in which brain activity becomes 
uncommon and is characterized by abnormal neuronal firing, which 
eventually results in unprovoked and unpredictable epileptic seizures 
and the recurrent episode of sensory disturbance [1, 2]. Epilepsy may 
occur by genetic predisposition or by brain injury such as trauma. This 
induces a brief episode of loss or disturbance of consciousness with or 
without characteristic body movement and sudden electrical storm, 
which may or may not lead to seizure. Seizure is a symptom for 
epilepsy associated with synchronously active neurons [3]. Typically 
used medications to subside seizure include oral and intravenous 
dosage forms. Presently the first-line drug for the ailment is 
benzodiazepine I. V. Along with this, pre-hospital management of 
epileptic seizure is achieved by rectal diazepam, intranasal and buccal 
midazolam solution. These benzodiazepines have a faster onset of 
action but possess short half-life, CNS depression and inability to 
differentiate postictal symptoms with that of the drug side effect. 
These reasons limit its use for therapy. The second line drug is 
phenytoin and fosphenytoin [3], whose dose given even though I. V 
is large (1.5g). The next choice of drug for the treatment comprises 
of Phenobarbital sodium, which is long-acting and cost-effective. But 
its current route of administration involves intravenous route that 
requires a skilled professional for administration and needs a sterile 
environment and also the oral administration possess delayed onset 
of action, poor bioavailability and interference of hepatic first-pass 
metabolism [4, 5]. High dose of Phenobarbital sodium (150 mg) is 
given intravenously to provide clinical benefit due to the inefficient 
delivery of drugs into the brain that leads to potential adverse 
effects [6].  
Moreover, the oral tablet of Phenobarbital sodium takes at least 30 
min to initiate its action. A rapid seizure control is mandatory to 
prevent the long term consequences in the brain, including neuronal 
damage, brain injury and, eventually, brain death. Unlike other routes, 
sublingual routes are superior due to its ability to absorb and produce 
action in seconds [7-9]. The degree of absorption is higher in the 
sublingual area when compared to other oral routes since the 
thickness of the sublingual area is 100-200 µm. Moreover, the 
polymer used is pullulan, which is biodegradable, non-hygroscopic, 
non-reactive, possess the mucoadhesive property and is a fast-
dissolving polymer [10] and thereby providing management of 
epileptic seizure. The optimum brain concentration of Phenobarbital 
sodium for anticonvulsant activity is 7-9µg/ml [12]. It would be 
appreciable if dose reduction is done since only a minimal 
concentration is required for its anticonvulsant effect. Considering 
these, it is important to formulate a sublingual patch using adequate 
excipients along with the drug. Apart from pullulan, propylene glycol 
is used as a plasticizer to maintain its flexibility, clove oil used as a 
permeation enhancer and citric acid as saliva stimulating agent [13]. 
Using these agents, it was able to formulate a fast-dissolving 
sublingual patch of Phenobarbital sodium that showed a faster 
release pattern, which would be promising for the management of 
epilepsy [14, 15].  
MATERIALS AND METHODS 
Materials and excipients  
Phenobarbital sodium API was gifted by Malladi Drugs and 
Pharmaceuticals Ltd, India and Pullulan were gifted by Gangwal 
chemicals pvt. Ltd, Bhiwandi. Propylene glycol was obtained from 
Choice Organochem Ltd, Mumbai, Citric acid was obtained from 
Fisher Scientific, the United States and Clove oil was obtained from 
Manohar Botanical Extracts pvt. Ltd. Kochi, All the chemicals used 
were of analytical grade [16]. 
Preformulation studies 
Solubility 
Solubility of the drug was checked in various solvents, including 
Methanol, Distilled water, Ethanol, Phosphate buffer saline (PBS) pH 
6.8 [17]. 
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Melting point 
Melting point of the obtained drug sample indicates the purity of the 
sample. The presence of impurities in drug samples leads to a low 
melting point. Open capillary method was used to determine the 
melting point of the sample [19]. 
Partition coefficient 
Partition coefficient of Phenobarbital sodium in n-octanol was found 
out [20]. The formed aqueous layer and organic phase were 
separated and the distribution of solute in both phase were 
determined by UV spectroscopy at 235 nm.  
Formulation of phenobarbital sodium loaded sublingual patches 
Phenobarbital sodium loaded sublingual patches were prepared by 
the solvent casting method [21-23]. From the preliminary 
physicochemical evaluation of the patches prepared, the suitable 
composition was used for the incorporation of Phenobarbital 
sodium. A natural polymer, pullulan was used as the main polymer 
along with the addition of propylene glycol as a plasticizer [24]. 
Clove oil was used as a permeation enhancer, and Citric acid was 
used as a saliva stimulating agent [25, 26]. Calculated amount of 
Phenobarbital sodium (1% (equivalent to 200 mg)) in methanol (9:1 
ratio) was dissolved in the polymeric solution of pullulan (6.5-8.5%) 
and propylene glycol (4%). After complete dissolution of the drug, 
citric acid (0.005%) and clove oil (0.005%) was added and stirred 
using a magnetic stirrer for 30 min at 600 rpm to form a homogeneous 
solution [27, 28]. The solution was casted on petridish, initially coated 
with glycerin, then kept in a hot air oven at temperature 45±5 °C for 
24 h [29]. The patch thus formed was cut into a size of 1×1 cm2 
diameter [30]. The formulation compositions of Phenobarbital sodium 
loaded sublingual patches were shown in table 1. 
 
Table 1: Formulation composition of Phenobarbital sodium loaded sublingual patches 








Clove oil (%) Distilled 
water(ml) 
1. S1 1 6.5 4 0.005 0.005 qs.20 
2. S2 1 7 4 0.005 0.005 qs.20 
3. S3 1 7.5 4 0.005 0.005 qs.20 
4. S4 1 8 4 0.005 0.005 qs.20 
5. S5 1 8.5 4 0.005 0.005 qs.20 
  
Preparation of backing membrane  
A solvent casting film method was used to prepare the PVA-
Aluminium backing membrane, is an impermeable substance that 
protects the product during use [31]. It was then casted on 
aluminum foil in a petridish at 50 °C by pouring 5 percent w/v 
aqueous solution of PVA and left for 8 h so as to get dry patch of 
drug impermeable backing membrane [32]. The patches of the 
appropriate size were then cut and stored in a suitable condition. 
Physicochemical evaluation of prepared Phenobarbital sodium 
loaded sublingual patches 
The Physico-chemical evaluation studies of prepared Phenobarbital 
sodium loaded patches are enlisted below 
Thickness uniformity of the patches 
The thickness of the prepared patches of each formulation of size 
1×1 cm2were measured using a screw gauge with least count at 
three different sites, and the average value was calculated [33]. 
Uniformity of weight of the patches 
Three patches of each formulation of size 1×1 cm2 were randomly 
subjected to weight variation by individually weighing the selected 
patches and the average was determined [34]. 
Folding endurance 
Three patches of each formulation of size 1×1 cm2 were sliced using a 
sharp blade. The folding endurance of patches was determined by 
folding a patch continuously at the same place until it appeared to crack. 
It was calculated as the number of times the patch is folded in the same 
position to either split the patch or produce noticeable cracks. The mean 
value with standard deviation was then determined [35, 36]. 
Surface pH determination  
The surface pH was determined to keep the pH as close to neutral as 
possible. For this purpose, a combined pH-electrode was used. Patch of 
each formulation of size 1×1 cm2 had been slightly wet with 1 ml of 
distilled water. The pH was determined by making the electrode came 
in contact with the patch surface. The procedure was carried out in 
triplicate, and standard deviation was reported on average [37].  
Percentage swelling index 
Three patches of each formulation were cut into 1×1 cm2 and 
initially weighted and kept immersed in 50 ml PBS pH 6.8. Taken out 
and weighed at time intervals of 5, 10, 30 and 60 min until a 
constant weight was obtained [38]. 
Percentage of moisture absorption 
To evaluate the physical stability of the patches under high humidity 
conditions, the accurately weighed 3 patches of size 1×1 cm2 and 
was placed in a desiccator containing saturated Aluminium chloride 
solution (79.5 % w/w relative humidity) for 3 d [39, 40]. 
Drug content uniformity 
Patch from each formulation of size 1×1 cm2 was dissolved in 
methanol and continuously shaken until the patch dissolved. After 
filtration, followed by proper dilution of methanol, the absorbance 
was measured at a wavelength of 235 nm and percentage drug 
content was then calculated. Methanol alone is the blank solution. 
The drug content determination was carried out in triplicate for all 
the formulations and the average percentage value with standard 
deviation was recorded [41]. 
Disintegration time 
The disintegration time, in this case, is the time when an oral patch 
or film begins to break when it comes in contact with saliva or 
sublingual pH. The disintegration time should be in the range 5-30 
sec for a fast-dissolving film or patch. United State Pharmacopoeia 
(USP) disintegration apparatus can be used to study disintegration 
time. In another method, the disintegration time can be visually 
determined by dipping the drug-loaded patch of size 1×1 cm2 into 25 
ml of PBS pH 6.8 buffer in a beaker. The beaker should be shaken 
gently, and the time when the film or patch begins to break or 
disintegrate was noted and the triplicate value was taken [42]. 
In vitro drug release study 
The studies of in vitro drug release of various formulations 
of Phenobarbital sodium loaded sublingual patches were done using 
static dissolution method. The apparatus was assembled 
by introducing an open-end tube vertically aligned to a beaker 
containing 50 ml of PBS pH 6.8, which acts as a receptor compartment 
[43]. The one end of the open end tube was tied with a cellophane 
membrane (molecular weight 12000-14000 D) which resembles the 
membrane acting as a barrier within the body so that only the tip 
touches the buffer solution surface. Reaction conditions have been 
standardized throughout the study. In the donor compartment, 1×1 
cm2 of the Phenobarbital sodium loaded sublingual patch was placed. 
The beaker was placed on a magnetic stirrer for 30 min and 1 ml of 
sample was taken at regular intervals. For each withdrawal, 1 ml of 
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fresh PBS pH 6.8 was replaced in the beaker and the samples collected 
were diluted using the same. The cumulative percentage of drug 
released in to the receptor medium at regular intervals was 
spectrometrically evaluated at 239 nm using a UV visible 
spectrophotometer. All these studies were done in triplicate [44]. 
Kinetic models of In vitro drug release study 
In order to examine the release mechanism of the drug from the 
optimized sublingual patch, the percentage cumulative drug release 
values were fitted into various kinetic models such as Zero-order 
kinetics, First-order kinetics, Higuchi model and Korsemeyer–
Pappas release kinetics to identify the in which model of release 
does the formulation is best fitted [45]. 
RESULTS AND DISCUSSION 
Preformulation studies 
Solubility 
Phenobarbital sodium is freely soluble in distilled water and soluble 
in methanol ethanol and PBS pH 6.8 [46]. 
Partition coefficient 
Partition coefficient of the drug was found to be 2.14, indicating that 
the drug possesses optimum lipid solubility [47]. 
 
 
Fig. 1: (A) Absorption maxima of phenobarbital sodium in PBS pH 6.8, (B) Absorption maxima of Phenobarbital sodium in methanol 
 
Lambda max of the phenobarbital sodium in phosphate buffer 
saline (PBS) pH 6.8 
The Lambda max of the drug in phosphate buffer saline (PBS) pH 6.8 
was found to be 239 nm, and was in accordance with the official 
standard. The absorption maxima of Phenobarbital sodium in PBS 
pH 6.8 were shown in fig. 1(A) 
Lambda max of the phenobarbital sodium in methanol 
The Lambda max of the Phenobarbital sodium in methanol was 
found to be 235 nm and was in accordance with the official standard 
[48]. The absorption maxima of Phenobarbital sodium in methanol 
were shown in fig. 1(B) 
Preparation of calibration curve of phenobarbital sodium in 
PBS pH 6.8 
The absorption values of the standard Phenobarbital sodium drug 
solution containing 20-120μg/ml of drug in pH 6.8 at the maximum 
wavelength of 239 nm is plotted. PBS of pH 6.8 provided similar pH 
as that of the sublingual fluid; thus it facilitates comparison of the 
results to in vivo conditions. The concentration used was in 
accordance with beer-lambert’s law [49]. The calibration curve was 
shown in fig. 2(A)  
Preparation of calibration curve of phenobarbital sodium in 
methanol 
The calibration curve was found to be linear in the concentration 
range of 20-120μg/ml at a wavelength of 235 nm [fig. 2(B)] 
Formulation of phenobarbital sodium loaded sublingual patches 
In this study, Phenobarbital sodium loaded sublingual patches were 
prepared by the solvent casting method using biodegradable natural 
polymer pullulan. Priya et al. (2016) [50] described the perks of using 
pullulan as a film former. Apart from these advantages, it has a 
mucoadhesive property, which could help in retaining the formulation 
upon administration. It has been identified that the clove oil has a 
higher permeation index, which would accounts for the immediate 
permeation of drugs through the sublingual area to encourage instant 
therapeutics. In order to stimulate the production of saliva, an agent 
should be incorporated, which was citric acid. Propylene glycol acts as 
a good plasticizer that helps in maintaining the flexibility of the patch. 
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These factors led to the selection of pullulan, clove oil, citric acid and 
propylene glycol as excipients in the formulation [51]. The patches 
were prepared with polymer concentration varying from 6.5-8.5 %. 
Patches with concentration below 6.5% were found to be sticky and 
were unable to be peeled out from the petridish. The varying 
concentration of pullulan above 6.5% with an optimized concentration 
of propylene glycol gave flexible and easily removable patches. The fig. 
3 showed the picture of the Phenobarbital sodium loaded sublingual 
patch. A Backing membrane of PVA-Aluminium was also made using 
the solvent casting method. It is impermeable in nature and protects 
the patch formulation during its use, which follows a unidirectional 
drug release pattern. Backing membrane being compatible provides a 
good bond with the drug reservoir, thus preventing the drug from 
leaving the dosage through top. 
 
 
Fig. 2: (A)The standard calibration curve of the pure drug of Phenobarbital sodium in PBS pH 6.8 with slope, intercept and regression 
coefficient, (B) The standard calibration curve of the drug phenobarbital sodium in methanol with slope, intercept and regression 
coefficient, (Values are expressed as mean±standard deviation, n=3) 
 
 
Fig. 3: Formulation of phenobarbital sodium loaded sublingual 
patch 
 
Physicochemical evaluation of prepared Phenobarbital sodium 
loaded sublingual patches  
Physicochemical properties  
The physicochemical evaluation data were tabulated in the table 2 
Thickness uniformity of patches 
The thickness of the prepared sublingual patches varied from 
0.23±0.62 mm to 0.39±0.69 mm [fig. 4(A)]. The patches were evenly 
distributed in the petridish. The thickness of S4 is 0.29±0.89 mm, 
which is adequate to be placed in the sublingual area [52]. 
Uniformity of weight of patches 
The average weight of the patches varied from 118 mg±0.75 to 133 
mg±0.87 for S1-S5 formulations, of which S4 has an optimum 
average weight, which is 124±0.57 mg [fig. 4(B)]. 
Folding endurance 
The folding endurance of various patches varied from 56±1.03 to 
162±1.05. It has been found that a good patch should have folding 
endurance above 150, which was shown by S4 (162±1.05) [fig. 4(C)]. 
The folding endurance values did not change much when a 
comparison was made between bare patches and the drug-loaded 
patches. Furthermore, the obtained result promises that it will 
endure stresses that would be encountered in the area of 
administration.  
Surface pH determination 
The surface pH of all the formulations S1-S5 was found to in the range 
6.41±0.69 to 6.76±1.06 [fig. 4(D)] indicating that all the formulations 
were non-irritant to oral as well as sublingual mucosa [53]. 
Percentage swelling index 
The swelling index of the patches S1-S5 ranged from 13 %±0.84 to 
34 %±1.38 [fig. 5(A)]. As the concentration of pullulan increased 
more than an optimum concentration, the swelling property 
decreased. S4 formulation (34 %±1.38) got a maximum swelling 
index.
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Fig. 4: (A) Mean thickness of various drug loaded sublingual formulations (S1-S5), (B) Mean average weight of formulations S1-S5, (C) 




Fig. 5: (A) Disintegration time of the formulations S1-S5, (B) Mean drug content uniformity of the formulations S1-S5, (C) Mean % swelling 
index of formulations S1-S5, (D) Mean surface pH of formulations S1-S5, (values are expressed as mean±standard deviation, n=3) 
 
Table 2: The physicochemical evaluation data of various drug loaded sublingual formulations (S1-S5), (values are expressed as 
mean±standard deviation, n=3) 













time (Sec)  
S1 0.39±0.62  133±0.87 56 ±1.03 6.41±0.69 13±0.84 5.19±0.76 83.39±0.91 16 ±0.87 
S2 0.36±1.02 129±0.99 78±0.76 6.46±0.76 17±1.24 5.17±1.21 89.56±1.13 13±1.51 
S3 0.31±1.32 127±0.65 96±1.34 6.54±0.90 25±1.13 5.12±0.87 93.89±1.02 14±2.18 
S4 0.29±0.89 124±0.57 162±1.05 6.76±1.06 34±1.38 5.08±0.79 96.78±0.82 09±1.24 
S5 0.23±0.69 118±0.75 114±0.45 6.63±1.09 31±1.99 5.04±1.14 86.34±0.89 11±1.94 
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Percentage of moisture absorption 
The percentage moisture absorption of the Phenobarbital sodium 
encapsulated patch was found to be between 5.19 %±0.76% to 5.04 
%±1.14 [fig. 5(B)]. All formulation possess percentage moisture 
absorption around 5%. The lesser the percentage moisture 
absorption the more the patches will be stable at humid conditions.  
Drug content uniformity 
All the formulations exhibited good drug content. Among them, S4 
exhibited the highest drug content, with 96.78±0.82 % [fig. 5(C)]. 
The obtained value depicts that the homogenous distribution of drug 
content has been achieved [54]. 
Disintegration time  
The disintegration time of all formulation varied from 09±1.24 to 
16±0.87 sec. Among them, S4 disintegrates at a faster rate 
(09±1.24). This suggests that the formulated patches will get fastly 
disintegrated in the sublingual fluid pH within few seconds and the 
drug will be then permeated instantly [fig. 5(D)]. 
In vitro drug release study 
The in vitro drug release study gave an idea regarding the amount of 
the drug that is available for absorption into the systemic circulation 
[55]. The release profile of drug predicts the in vivo behaviour of the 
drug in the circulation. The drug release study was carried out using 
a phosphate buffer solution (PBS) of 6.8 since the pH of the 
sublingual fluid is in this range. The cumulative percentage drug 
released from each formulation v/s time curve was plotted at 
different time intervals. The cumulative percentage drug released 
for all formulations varied from 75.97±2.48% to 96.24±1.27 % at 
the end of 60 min. A significant release was shown within first 30 
seconds by all the formulation specifically by S4 formulation 
(20.84±1.97%) and about 50% of the drug was also released within 
8 min of which S4 showed 77.22±2.4% release compared to other 
formulations. This drug release pattern is substantial as the drug 
could reach systemic circulation at a faster rate that ultimately 
results in rapid onset of action. After 60 min, the patch lost its 
stability and integrity and was not suitable for further studies. The 
S4 formulation showed a maximum release of 96.24±1.27 % when 
compared to other formulations. Upon analysing the release data 
and physicochemical parameters, the S4 formulation was considered 
to be the optimized one and was further selected for the remaining 
study. With the aid of biocompatible polymer pullulan and 
permeation enhancing the capability of clove oil may have resulted 
in accelerating the drug release from the formulation [56]. Finally, 
the kinetic model determination of the optimized formulation S4 
was also carried out. The in vitro drug release data of prepared S1-S5 
formulations were shown in fig. 6(A). 
 
 
Fig. 6: (A) In vitro drug release of prepared S1-S5 formulations, (B) In vitro drug release model fitting data of optimized Phenobarbital 
sodium loaded sublingual patch (S4), (Values are expressed as mean±standard deviation, n=3) 
 
Table 3: In vitro drug release model fitting data of optimized phenobarbital sodium loaded sublingual patch (S4), (values are expressed as 
mean±standard deviation, n=3) 
Zero-order release plot  First-order release plot Higuchi plot  Korsemyer peppas plot  Best fitted model 
R2R2 R2 R2 n R2 Higuchi plot 
0.9544 0.9123 0.9903 0.36 0.889 
 
Kinetic models of In vitro drug release study 
The drug release profile of optimized Phenobarbital sodium loaded 
sublingual patch (S4) was attributed to different kinetic models like 
zero order, first order, Higuchi diffusion model and Koresmeyer 
Peppas plot to interpret drug release by kinetic modeling [57] [fig. 
6(B)]. The release kinetics of the drug Phenobarbital sodium was 
found to be Higuchi diffusion model with the highest regression 
coefficient value, R2= 0.9903. Hence we can conclude that the 
optimized formulation showed rapid release from the polymer 
matrix by diffusion as it was the best fit in the higuchi model [58]. 
Stability study 
The stability study of the optimized Phenobarbital sodium loaded 
sublingual patch (S4) was carried out for 3 mo at refrigerator 
temperature (4±2 °C) and its physical changes like colour, 
flexibility, texture and physicochemical characters like 
disintegration time and folding endurance were estimated at an 
interval of one month [59]. The physical appearance of the patch 
was retained and did not show any change after 3 mo on 
comparing with the freshly prepared patch at refrigeration. The 
disintegration time and folding endurance of the patch was 
determined for 0 mo, 1st, 2nd and 3rd month, respectively and was 
shown in fig. 7(A) and fig. 7(B). The results of the study indicated 
that there were no significant changes observed in the 
disintegration time and folding endurance when stored at 
refrigerated temperature even after 3 mo [60]. Thus the result of 
stability study confirmed that the optimized Phenobarbital sodium 
loaded sublingual patch S4 remained stable at refrigerated 
temperature (4±2 °C) for three months. 
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Fig. 7: (A) Stability data showing the disintegration time of optimized Phenobarbital sodium loaded sublingual patch (S4) formulation, (B) 
Stability data showing the Folding endurance of optimized Phenobarbital sodium loaded sublingual patch (S4) formulation, (values are 
expressed as mean±standard deviation, n=3) 
 
CONCLUSION 
Epilepsy is a disorder of the brain characterized by an enduring 
predisposition to generate seizures. Several routes for the 
administration of anti-epileptic drug have been identified but none 
seems to be completely effective. Sublingual patches gained 
applicability in drug delivery system as a novel, convenient and easily 
administrable form of the drug product. Furthermore, the degree of 
absorption through the sublingual route is higher when compared to 
other routes and hence could deliver the drug at much faster rate, 
which is mandatory in our ailment of interest. Phenobarbital sodium 
loaded sublingual patches were prepared by the solvent casting 
method using biodegradable, biocompatible natural polymer pullulan 
with clove oil as a permeation enhancer, propylene glycol as a 
plasticizer and citric acid as saliva stimulant. The optimised sublingual 
patches of Phenobarbital sodium (S4) provided a maximum drug 
release within short span of time with diffusion mediated release 
mechanism. The S4 formulation retained its physicochemical 
properties even when it was subjected to refrigerated condition, 
depicting its stable nature. Thus the optimized Phenobarbital sodium 
loaded pullulan based sublingual patch was found to be promising for 
the sublingual delivery of drug for the management of epileptic 
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